CAPTRUST Financial Advisors
SUPN icon

CAPTRUST Financial Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

CAPTRUST Financial Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.95M Buy
41,958
+1,706
+4% +$81.9K ﹤0.01% 1319
2026
Q1 		$2.08M Buy
40,252
+21,649
+116% +$1.1M ﹤0.01% 1201
2025
Q4 		$925K Buy
18,603
+188
+1% +$9.14K ﹤0.01% 1555
2025
Q3 		$880K Sell
18,415
-1,997
-10% -$80.4K ﹤0.01% 1502
2025
Q2 		$643K Buy
20,412
+2,681
+15% +$85.9K ﹤0.01% 1583
2025
Q1 		$581K Buy
17,731
+337
+2% +$11.9K ﹤0.01% 1573
2024
Q4 		$629K Buy
17,394
+7,969
+85% +$281K ﹤0.01% 1491
2024
Q3 		$294K Sell
9,425
-819
-8% -$25.6K ﹤0.01% 1887
2024
Q2 		$274K Sell
10,244
-87
-0.8% -$2.52K ﹤0.01% 1862
2024
Q1 		$352K Buy
10,331
+1,474
+17% +$43.9K ﹤0.01% 1682
2023
Q4 		$256K Sell
8,857
-1,502
-14% -$39.8K ﹤0.01% 2218
2023
Q3 		$286K Buy
+10,359
New +$315K ﹤0.01% 2021
2023
Q2 		– Sell
-6,250
Closed -$226K – 2588
2023
Q1 		$226K Buy
6,250
+209
+3% +$8.04K ﹤0.01% 1966
2022
Q4 		$215K Buy
6,041
+127
+2% +$4.41K ﹤0.01% 1901
2022
Q3 		$200K Buy
5,914
+2,710
+85% +$88.2K ﹤0.01% 1823
2022
Q2 		$93K Buy
3,204
+221
+7% +$6.33K ﹤0.01% 2252
2022
Q1 		$96K Buy
2,983
+1,850
+163% +$56.7K ﹤0.01% 2309
2021
Q4 		$33K Buy
1,133
+91
+9% +$2.76K ﹤0.01% 2969
2021
Q3 		$28K Buy
1,042
+146
+16% +$3.92K ﹤0.01% 2949
2021
Q2 		$28K Sell
896
-20
-2% -$613 ﹤0.01% 2893
2021
Q1 		$24K Buy
916
+641
+233% +$17.9K ﹤0.01% 2897
2020
Q4 		$7K Buy
275
+50
+22% +$1.08K ﹤0.01% 2714
2020
Q3 		$5K Buy
225
+50
+29% +$1.14K ﹤0.01% 2543
2020
Q2 		$4K Buy
+175
New +$3.87K ﹤0.01% 2462
2019
Q4 		– Sell
-130
Closed -$4K – 1706
2019
Q3 		$4K Hold
130
– – ﹤0.01% 1697
2019
Q2 		$4K Buy
+130
New +$4.45K ﹤0.01% 1705
2018
Q3 		– Sell
-15
Closed -$1K – 1694
2018
Q2 		$1K Buy
+15
New +$777 ﹤0.01% 1469

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

CAPTRUST Financial Advisors's SUPN Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 4.2% in Q2 2026, buying an estimated $81.9K and bringing the position to 41,958 shares worth $1.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1319.

CAPTRUST Financial Advisors first reported a position in SUPN in Q2 2018 and has held it in 27 quarters since. The position peaked at $2.08M in Q1 2026. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • CAPTRUST Financial Advisors held 41,958 shares of Supernus Pharmaceuticals worth $1.95M as of Q2 2026.
  • CAPTRUST Financial Advisors bought 1,706 Supernus Pharmaceuticals shares in Q2 2026, an estimated $81.9K.
  • Supernus Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #1319 holding.
  • CAPTRUST Financial Advisors first reported a position in Supernus Pharmaceuticals in Q2 2018 and has held it in 27 quarters since.
  • CAPTRUST Financial Advisors's Supernus Pharmaceuticals position peaked at $2.08M in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.